平时缺乏体育锻炼、肥胖、高血压、高胆固醇、吸烟、糖尿病等因素都会诱发冠心病。在美国，因冠心病导致的死亡率一直居高不下。
同样，前列腺癌是美国男性第二大致死性癌症类型。每年有240,000新增前列腺癌男性患者，每年有34,000前列腺癌患者死亡。
科学家们一直在探究这两种高发病--冠心病和前列腺癌之间是否有联系，因为如果一旦确定心血管疾病是前列腺癌致病的危险因素，那么我们或许可以通过改变生活方式来一定程度上抑制肿瘤的发生发展。但研究结果却不尽如人意。科研人员一直无法肯定那些引发冠心病的不良生活习惯会不会也导致前列腺癌的发生。
近日，由Duke癌症研究所研究人员进行的一项前列腺药物试验的大样本分析研究中，研究者发现冠心病和前列腺癌之间有着显著相关性，这一研究结果提示这两种疾病也许有相同的致病因素。相关研究论文发表在Cancer Epidemiol Biomarkers Prev杂志。
在Duke癌症研究所研究人员进行的持续四年的随机试验中，工作者运用6,390名前列腺癌男性患者资料去评估抗肿瘤药物Dutasteride对前列腺癌的作用。前列腺癌患者在分别在第二年和第四年两年进行了两次前列腺生物活检，检测了PSA水平。同时研究人员收集了患者详细的疾病史、体重、酒精摄入情况、药物使用等因素的信息。
在6,390名前列腺癌男性患者中，有547人有冠心病史。这些有冠心病史的前列腺癌男性患者PSA水平基线较高，同时患有糖尿病等代谢疾病。结果证实了冠心病使得男性患前列腺癌的风险增加了35%，并且之一风险率随着年龄的增长而增加。
研究人员表示：我们或许可以改变不良的生活习惯，控制冠心病发生的因素如高血压、糖尿病等从而能降低我们患前列腺癌的风险。(生物谷 Bioon.com)
doi:10.1158/1055-9965.EPI-11-1017
PMC:
PMID:
Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE study
Jean-Alfred Thomas1,*,Leah Gerber2,Lionel L. Banez3,Daniel M. Moreira4, et al.
Background:Coronary artery disease (CAD) and prostate cancer (PCa) are not only common diseases, but share many risk factors. To date, only a few studies have explored the relationship between CAD and PCa risk, with conflicting results. Methods:The 4-year REDUCE study tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA of 2.5-10.0 ng/mL and a negative biopsy. Among men who underwent at least one on-study biopsy (n=6,729; 82.8%), the association between CAD and overall PCa risk and disease grade was examined using logistic and multinomial logistic regression adjusting for clinicopathological features, respectively. Results:Overall, 547 men (8.6%) had a history of CAD. Men with CAD were significantly older and had higher BMI, PSA and larger prostate volumes and were more likely to have diabetes, hypertension, and hypercholesterolemia and take aspirin and statins. On multivariate analysis, CAD was associated with a 35% increased risk of PCa diagnosis (OR: 1.35, 95% CI: 1.08-1.67, p=0.007), while elevating risk of both low- (OR: 1.34, 95% CI: 1.05-1.73, p=0.02), and high-grade disease (OR: 1.34, 95% CI: 0.95-1.88, p=0.09). Conclusions:In a post-hoc hypothesis developing secondary analysis of the REDUCE study, CAD was significantly associated with increased PCa diagnosis. Impact: If confirmed in other studies, this suggests CAD may be a novel PCa risk factor and suggests common shared etiologies. Whether lifestyle changes shown to reduce CAD risk (i.e. weight loss, exercise, cholesterol reduction, etc.) can reduce PCa risk, warrants further study.
